Armodafinil
From Psychology Wiki
Community portal · Tasks to do · News · Help
Clinical · Educational · Ind&Org · Other fields · Professional · Transpersonal · World
Assessment | Biopsychology | Comparative | Cognitive | Developmental | Language | Personality | Philosophy | Research Methods | Social | Statistics
Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology
|
Image:(R)-modafinil.png | |
| (-)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide IUPAC name | |
| CAS number 68693-11-8 | ATC code |
| PubChem [1] | DrugBank [2] |
| Chemical formula | {{{chemical_formula}}} |
| Molecular weight | 273.351 |
| Bioavailability | |
| Metabolism | Hepatic, including CYP3A4 and other pathways |
| Elimination half-life | 12-15 hrs |
| Excretion | Urine (as metabolites) |
| Pregnancy category | C |
| Legal status | Schedule IV (USA) |
| Routes of administration | Oral |
Armodafinil (Nuvigil®) is an eugeroic drug produced by the pharmaceutical company Cephalon Inc., currently in the process of receiving Food and Drug Administration (FDA) approval. Armodafinil is the r-enantiomer of modafinil, so is expected to act in a similar manner, with similar effects. However, it acts for a longer duration of time than modafinil. Cephalon hopes to soon release the longer-lasting Nuvigil (R-modafinil) as a "truly once-a-day" wakefulness medication. In 2006, the FDA sent Cephalon an "approvable letter" for Nuvigil, pending agreement on the final product labeling. Upon approval, it is expected to be classified as a Schedule IV controlled substance.
[edit] See also
[edit] External links
| Stimulants edit |
|---|
- gl:Armodafinil
| This page uses content from the English-language version of Wikipedia. The original article was at Armodafinil. The list of authors can be seen in the page history. As with Psychology Wiki, the text of Wikipedia is available under the GNU Free Documentation License. |
